CS Mckee LP boosted its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 0.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 42,050 shares of the specialty pharmaceutical company’s stock after purchasing an additional 200 shares during the quarter. CS Mckee LP owned about 0.08% of Supernus Pharmaceuticals worth $1,812,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. lifted its stake in shares of Supernus Pharmaceuticals by 0.5% in the second quarter. BlackRock Inc. now owns 6,727,641 shares of the specialty pharmaceutical company’s stock valued at $289,962,000 after buying an additional 31,331 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Supernus Pharmaceuticals by 39.1% in the second quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock valued at $150,873,000 after buying an additional 984,200 shares in the last quarter. Ranger Investment Management L.P. lifted its stake in shares of Supernus Pharmaceuticals by 2.8% in the first quarter. Ranger Investment Management L.P. now owns 1,482,535 shares of the specialty pharmaceutical company’s stock valued at $46,403,000 after buying an additional 40,131 shares in the last quarter. State Street Corp lifted its stake in shares of Supernus Pharmaceuticals by 3.1% in the second quarter. State Street Corp now owns 1,397,484 shares of the specialty pharmaceutical company’s stock valued at $60,230,000 after buying an additional 42,165 shares in the last quarter. Finally, Rice Hall James & Associates LLC lifted its stake in shares of Supernus Pharmaceuticals by 24.5% in the second quarter. Rice Hall James & Associates LLC now owns 1,361,373 shares of the specialty pharmaceutical company’s stock valued at $58,675,000 after buying an additional 267,971 shares in the last quarter. 95.36% of the stock is currently owned by hedge funds and other institutional investors.

In related news, VP Padmanabh P. Bhatt sold 3,709 shares of the stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $45.23, for a total transaction of $167,758.07. Following the sale, the vice president now directly owns 17,500 shares of the company’s stock, valued at approximately $791,525. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Padmanabh P. Bhatt sold 3,735 shares of the stock in a transaction dated Wednesday, July 12th. The shares were sold at an average price of $44.90, for a total transaction of $167,701.50. Following the sale, the vice president now directly owns 21,209 shares in the company, valued at $952,284.10. The disclosure for this sale can be found here. Insiders have sold a total of 157,444 shares of company stock worth $7,390,810 over the last three months. 6.70% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: “CS Mckee LP Boosts Holdings in Supernus Pharmaceuticals, Inc. (SUPN)” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/10/09/cs-mckee-lp-boosts-holdings-in-supernus-pharmaceuticals-inc-supn.html.

Supernus Pharmaceuticals, Inc. (NASDAQ SUPN) traded down 3.07% on Monday, hitting $41.10. 167,624 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $43.73 and a 200-day moving average price of $38.90. Supernus Pharmaceuticals, Inc. has a 52-week low of $17.25 and a 52-week high of $50.04. The stock has a market cap of $2.08 billion, a P/E ratio of 20.74 and a beta of 1.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. The company had revenue of $75.83 million for the quarter, compared to the consensus estimate of $68.54 million. Analysts predict that Supernus Pharmaceuticals, Inc. will post $1.04 earnings per share for the current fiscal year.

A number of research analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $49.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 27th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $41.00 price objective on shares of Supernus Pharmaceuticals in a research note on Tuesday, September 26th. Cowen and Company reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Supernus Pharmaceuticals in a research note on Thursday, September 21st. Jefferies Group LLC reaffirmed a “buy” rating and issued a $51.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 20th. Finally, Janney Montgomery Scott reaffirmed a “hold” rating and issued a $47.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, September 20th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Supernus Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $47.71.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.